Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation Strategies

As bispecific T-cell engagers (TCEs) gain traction in the oncology treatment landscape, cancer centres must develop robust clinical pathways to ensure their safe and efficient delivery. Given the limited experience of the Canadian medical oncology community with TCEs, collecting and publishing early...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Parneet K. Cheema, Kirstin A. Perdrizet, Randeep S. Sangha, Daniel Breadner, Nathalie Daaboul, Shannon Farley, Kevin Jao, Geoffrey Liu, Becky Logan, Barbara Melosky, Anthony Reiman, Stephanie Snow, Sunil Yadav, Shaqil Kassam
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	MDPI AG 2026-01-01
Seri Bilgileri:	Current Oncology
Konular:	cytokine release syndrome immune effector cell-associated neurotoxicity syndrome bispecific antibody
Online Erişim:	https://www.mdpi.com/1718-7729/33/2/84
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation Strategies

Benzer Materyaller